A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
16 September, 2025
Expanded access to radiation therapy Talking Book to support Aboriginal and Torres Strait Islander consumers
LATEST NEWS: 16 September 2025 A ‘Talking Book’ which
26 August, 2025
Welcome to new TROG committee members and thank you to long-serving members
LATEST NEWS: 26 August 2025 The TROG Scientific Committee